ProCE Banner Activity

A041202: Phase III Trial of Ibrutinib ± Rituximab vs Bendamustine + Rituximab in Older Patients With Previously Untreated CLL

Slideset Download
Conference Coverage
2-year PFS was significantly increased with ibrutinib vs BR but was not further improved by addition of rituximab.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology